Antigen Discovery wins SBIR award
The three-year, $2.5m award is a continuation to phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens. As part of the research, ADi proteome
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.